Andrew Raubitschek

140 Phase I radioimmunotherapy trial evaluating 90Yttrium labeled anti-cea chimeric T84.66 in patients with metastatic cea-producing malignancies

James H. Doroshow, Anna M. Wu, Tamara Odom-Maryon, 1997 .

Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.

Paul J Yazaki, Anna M Wu, J. Wong, 2006, Bioconjugate chemistry.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

Daniel H. S. Silverman, Stewart Spies, William L. Dunn, 2000, European Journal of Nuclear Medicine.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Jinjuan Wang, Xiaojun Qian, D. Maloney, 2012, Blood.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

Hua Yu, Drew M. Pardoll, John J. Rossi, 2009, Nature Biotechnology.

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Jinjuan Wang, Brent L Wood, Xiaojun Qian, 2008, Blood.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

J. Wong, J. Shively, L. Williams, 2005, Bioconjugate chemistry.

A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Paul J Yazaki, J. Bading, J. Wong, 2008, Bioconjugate chemistry.